Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients.
Cytomegalovirus (CMV)-infection remains a major cause of morbidity and mortality after lung transplantation. Treatment with currently available drugs poses treatment difficulties in some patients due to drug resistance or intolerability. We report a series of four lung transplant recipients with CMV-infection and treatment failure upon standard care due to antiviral drug resistance and treatment limiting side effects. As rescue therapy letermovir, recently approved for the prophylaxis of CMV-infection in patients after hematopoietic stem cell transplantation was initiated. Patients received 480 mg per day for a follow up of 36.1 ± 12.9 weeks. Efficacy and tolerability was assessed retrospectively. Mild nausea, vomiting and diarrhea were the only side effects of letermovir reported by a single patient. A small adjustment of the tacrolimus dose was mandatory upon treatment initiation with letermovir. CMV-viral load could be decreased and cleared subsequently in all patients. CMV clearance was observed after 17.7 ± 12.6 weeks despite lack of CMV-immunity. CMV-infection and -disease were successfully managed with letermovir. Letermovir was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on currently available antiviral agents.